Neuraxis (NRXS) risk factors

50 risks, 2 reworded since the prior year. Neuraxis shifted from a sole manufacturer to relying on two contract manufacturers for product production. The AMA accepted a Category I CPT Code for PENFS replacing the old CAT III code, with utilization effective January 1, 2026.

50 risks. Neuraxis faces significant operating losses since 2011 while trying to commercialize neuromodulation therapies for children like the IB-Stim device. The business heavily relies on third-party manufacturers, single-source component suppliers, and adequate insurance reimbursement codes. Extensive FDA and international regulations govern clinical trials, quality systems, marketing, and ongoing product compliance.